To finance the next necessary pharmacokinetic and clinical trials, we are looking for new investors and experts who want to join our collaboration.
Will you join our cause and make easier cystinosis treatment accessible for all patients?
New investors, co-financing the clinical trial in 2023, will join the current investor pool, with the following conditions:
DIVIDEND & RECOUPMENT
Investors will receive accumulated dividend on their investment up until recoupment, which is projected to be five years after market introduction.
SUSTAINABLE PROFIT MARGIN
Investors will earn back their investment plus a pre-defined profit margin, contributing to the treatment’s accessibility.
Patient One will follow a cost-price-plus based pricing strategy, ensuring access for patients.
Interested? Let’s get in contact!